Metotrexato Accord (Methotrexate)

Methotrexate is a folate antagonist that competitively inhibits the enzyme dihydrofolate reductase. This blockade reduces the regeneration of tetrahydrofolate, a co‑factor required for synthesis of purine nucleotides and thymidylate, thereby decreasing DNA, RNA and protein production in rapidly dividing cells.

The prescribed dose of methotrexate is individualized by the treating physician based on the specific indication, patient weight or body surface area, renal and hepatic function, and any concurrent therapies. Dosing regimens differ between oncology protocols and rheumatologic or dermatologic treatment plans.

Methotrexate is classified as teratogenic and is generally contraindicated during pregnancy. Women of child‑bearing potential should use effective contraception before, during, and after therapy. Limited data exist for breastfeeding; most guidelines advise against nursing while on methotrexate because of potential infant exposure.

To place an order, submit an enquiry on the Metotrexato Accord product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain if required) and necessary import documentation.

For rheumatoid arthritis, methotrexate is often compared with leflunomide or biologic agents. Methotrexate offers a well‑established efficacy profile, oral or injectable options, and lower cost, but may require regular monitoring for hepatic and hematologic toxicity. Biologics target specific cytokines and may have different safety considerations.

Metotrexato Accord should be stored in a refrigerator at 2 °C to 8 °C. Keep the vials in their original packaging, protect them from light, and avoid freezing or shaking the solution. If temporary temperature excursions occur, follow the manufacturer’s stability guidelines before use.

The product is supplied as a sterile injectable solution and is administered by a qualified healthcare professional via intra‑arterial, intramuscular, or intrathecal injection, depending on the therapeutic indication and prescribed regimen. Administration techniques follow standard aseptic procedures.

Serious adverse events include severe liver toxicity (hepatitis or fibrosis), pulmonary fibrosis, bone marrow suppression leading to pancytopenia, and acute renal failure. Patients should be monitored regularly for liver enzymes, pulmonary symptoms, complete blood counts and renal function to detect these complications early.

Methotrexate is contraindicated in pregnant women, individuals with uncontrolled severe liver disease, significant renal impairment, active infections, or known hypersensitivity to the drug. Caution is also advised for patients with pre‑existing pulmonary disease or those receiving other myelosuppressive agents.